Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study - PubMed
3 hours ago
- #obesity care
- #semaglutide
- #real-world evidence
- Study evaluates real-world use of semaglutide in obese patients, focusing on titration, tolerability, and efficacy.
- 111 patients included (80% women, mean age 51.12, median BMI 35.56 kg/m²).
- 81.1% started at 0.25 mg, 72.1% increased to 1 mg by 3 months.
- By 6 months, 2% on 0.5 mg, 40% on 1 mg, 26% on 2.4 mg.
- Main reasons for dose maintenance: satisfaction with outcomes, cost, and adverse events.
- Significant reductions in weight, BMI, waist circumference, and waist-to-height ratio observed.
- 23.5%, 34.6%, 30.8%, and 11.1% achieved ≥5%, ≥10%, ≥15%, and ≥20% weight loss, respectively.
- Adverse events occurred in 56.8% at 3 months (3 discontinuations), halved to 32.6% by 6 months (2 discontinuations).
- Early discontinuation rates: 6.3% at 3 months, 10.5% at 6 months due to cost, adverse events, or inefficacy.
- Study confirms favorable efficacy profile with flexible dosing in routine clinical practice.